Key Takeaways Five biotech stocks are highlighted for 2026 due to late-stage trials or upcoming FDA decisions.MindMed expects multiple phase III data readouts in 2026 for its lead program MM120.Ocugen, Kyverna and Celcuity face key inflection points tied to BLAs or pivotal clinical data.After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements with the Trump administrati ...